Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 170

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Clinical Trials Express:Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)

Open access
Nakamura, Toshitaka, Matsumoto, Toshio, Sugimoto, Toshitsugu, Hosoi, Takayuki, Miki, Takami, Gorai, Itsuo, Yoshikawa, Hideki, Tanaka, Yoshiya, Tanaka, Sakae, Sone, Teruki, Nakano, Tetsuo, Ito, Masako, Matsui, Shigeyuki, Yoneda, Toshiyuki, Takami, Hideo, Watanabe, Ko, Osakabe, Taisuke, Shiraki, Masataka, Fukunaga, Masao · 2014 · The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT: Denosumab 60 mg sc injection every 6 months for 36 months was well tolerated and effective in reducing the incidence of vertebral, nonvertebral, and hip fracture in predominantly Caucasian postmenopausal women with osteoporosis. OBJECTIVE: The objective of this phase 3 fracture study was to examine the antifracture efficacy and safety of denosumab 60 mg in Japanese women and men with osteoporosis compared with placebo. DESIGN AND SETTING: A randomized, double-blind, placebo-controlled trial with an open-label active comparator as a referential arm was conducted. PATIENTS: Subjects were 1262 Japanese patients with osteoporosis aged 50 years or older, who had one to four prevalent vertebral fractures. INTERVENTION: Subjects were randomly assigned to receive denosumab 60 mg sc every 6 months (n = 500), placebo for denosumab (n = 511), or oral alendronate 35 mg weekly (n = 251). All subjects received daily supplements of calcium and vitamin D. MAIN OUTCOME MEASURE: The primary endpoint was the 24-month incidence of new or worsening vertebral fracture for denosumab vs placebo. RESULTS: Denosumab significantly reduced the risk of new or worsening vertebral fracture by 65.7%, with incidences of 3.6% in denosumab and 10.3% in placebo at 24 months (hazard ratio 0.343; 95% confidence interval 0.194-0.606, P = .0001). No apparent difference in adverse events was found between denosumab and placebo during the first 24 months of the study. CONCLUSION: These results provide evidence of the efficacy and safety of denosumab 60 mg sc every 6 months in Japanese subjects with osteoporosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2013-4175

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 170

Metadata

Authors
Nakamura, T., Matsumoto, T., Sugimoto, T., Hosoi, T., Miki, T., Gorai, I., Yoshikawa, H., Tanaka, Y., Tanaka, S., Sone, T., Nakano, T., Ito, M., Matsui, S., Yoneda, T., Takami, H., Watanabe, K., Osakabe, T., Shiraki, M., & Fukunaga, M.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2014-07-01
Volume
99
Issue
7
Pages
2599-2607
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2085717531
Cited by
170
References
1
FWCI
11.91
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Trials Express:Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). https://app.cochat.ai/papers/10.1210/jc.2013-4175
The paper
Nakamura, T., Matsumoto, T., Sugimoto, T., Hosoi, T., Miki, T., Gorai, I., Yoshikawa, H., Tanaka, Y., Tanaka, S., Sone, T., Nakano, T., Ito, M., Matsui, S., Yoneda, T., Takami, H., Watanabe, K., Osakabe, T., Shiraki, M., & Fukunaga, M. (2014). Clinical Trials Express:Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2013-4175

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.